Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDSX NASDAQ:CELC NYSE:HHLA NASDAQ:PSNL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSXBiodesix$0.36+2.9%$0.30$0.17▼$2.04$51.30M0.972.50 million shs1.47 million shsCELCCelcuity$13.94+3.0%$12.16$7.58▼$19.77$512.71M0.45266,542 shs293,560 shsHHLAHH&L Acquisition$10.75-0.3%$10.76$10.20▼$11.30$156.52M-0.01121,140 shs3,300 shsPSNLPersonalis$6.43+3.7%$5.82$2.61▼$7.79$547.62M1.951.06 million shs1.02 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSXBiodesix+9.61%+11.93%+33.59%-28.57%-80.23%CELCCelcuity-0.37%-1.53%+16.72%+21.76%-21.64%HHLAHH&L Acquisition0.00%0.00%0.00%0.00%0.00%PSNLPersonalis+0.16%-4.17%-3.43%+81.82%+61.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDSXBiodesix3.5516 of 5 stars4.45.00.00.00.02.50.6CELCCelcuity1.5264 of 5 stars3.51.00.00.00.62.50.0HHLAHH&L AcquisitionN/AN/AN/AN/AN/AN/AN/AN/APSNLPersonalis3.0933 of 5 stars2.51.00.04.20.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDSXBiodesix 2.80Moderate Buy$1.75386.11% UpsideCELCCelcuity 3.00Buy$28.25102.65% UpsideHHLAHH&L Acquisition 0.00N/AN/AN/APSNLPersonalis 3.00Buy$7.6719.23% UpsideCurrent Analyst Ratings BreakdownLatest CELC, HHLA, BDSX, and PSNL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025CELCCelcuityStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.006/30/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.005/21/2025BDSXBiodesixScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$3.00 ➝ $2.005/19/2025CELCCelcuityHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.005/15/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.005/15/2025PSNLPersonalisGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/14/2025BDSXBiodesixLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $2.005/14/2025BDSXBiodesixCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $1.505/14/2025BDSXBiodesixCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$2.50 ➝ $1.505/14/2025BDSXBiodesixWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform5/7/2025PSNLPersonalisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $9.00(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDSXBiodesix$71.32M0.74N/AN/A$0.14 per share2.57CELCCelcuityN/AN/AN/AN/A$3.11 per shareN/AHHLAHH&L AcquisitionN/AN/A$1.71 per share6.29($1.19) per shareN/APSNLPersonalis$84.61M6.71N/AN/A$2.87 per share2.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDSXBiodesix-$42.93M-$0.290.00N/AN/A-54.28%-167.28%-39.96%8/6/2025 (Estimated)CELCCelcuity-$111.78M-$3.030.00N/AN/AN/A-96.21%-49.44%8/13/2025 (Estimated)HHLAHH&L Acquisition$17.69M-$0.14N/A∞N/AN/A-57.47%-0.35%N/APSNLPersonalis-$81.28M-$1.290.00N/AN/A-98.10%-48.78%-34.70%8/6/2025 (Estimated)Latest CELC, HHLA, BDSX, and PSNL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025CELCCelcuity-$0.94N/AN/AN/AN/AN/A8/6/2025Q2 2025BDSXBiodesix-$0.07N/AN/AN/A$18.47 millionN/A8/6/2025Q2 2025PSNLPersonalis-$0.25N/AN/AN/A$20.12 millionN/A5/14/2025Q1 2025CELCCelcuity-$0.95-$0.86+$0.09-$0.86N/AN/A5/13/2025Q1 2025BDSXBiodesix-$0.08-$0.08N/A-$0.08$19.50 million$17.96 million5/6/2025Q1 2025PSNLPersonalis-$0.23-$0.18+$0.05-$0.18$17.41 million$20.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDSXBiodesixN/AN/AN/AN/AN/ACELCCelcuityN/AN/AN/AN/AN/AHHLAHH&L AcquisitionN/AN/AN/AN/AN/APSNLPersonalisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDSXBiodesix3.322.222.22CELCCelcuity1.146.616.61HHLAHH&L AcquisitionN/A0.030.03PSNLPersonalisN/A6.916.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDSXBiodesix20.96%CELCCelcuity63.33%HHLAHH&L Acquisition39.24%PSNLPersonalis61.91%Insider OwnershipCompanyInsider OwnershipBDSXBiodesix30.10%CELCCelcuity15.78%HHLAHH&L Acquisition0.54%PSNLPersonalis3.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDSXBiodesix220146.56 million102.45 millionOptionableCELCCelcuity4037.87 million31.89 millionOptionableHHLAHH&L AcquisitionN/A14.56 million14.48 millionNot OptionablePSNLPersonalis40088.32 million84.97 millionOptionableCELC, HHLA, BDSX, and PSNL HeadlinesRecent News About These CompaniesPersonalis to Announce Second Quarter 2025 Financial Results5 hours ago | businesswire.comPersonalis, Inc. (NASDAQ:PSNL) Stake Lifted by AIGH Capital Management LLCJuly 22 at 12:21 PM | marketbeat.comHead-To-Head Contrast: Personalis (NASDAQ:PSNL) & Acura Pharmaceuticals (OTCMKTS:ACUR)July 18, 2025 | americanbankingnews.comPersonalis, Inc. (PSNL) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comPersonalis Expands Tempus Strategic Collaboration to Bring Ultra ...July 11, 2025 | morningstar.comMPersonalis and Tempus extend cancer detection collaboration to 2029July 11, 2025 | investing.comPersonalis (NASDAQ:PSNL) Shares Down 6.1% - Time to Sell?July 10, 2025 | marketbeat.comPersonalis, Tempus Expand Detection Test to Include Colorectal CancerJuly 9, 2025 | marketwatch.comStocks to Watch: Nurix Therapeutics, Personalis, WK KelloggJuly 9, 2025 | marketwatch.comPersonalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer PatientsJuly 9, 2025 | finance.yahoo.comPersonalis, Inc. (NASDAQ:PSNL) Stake Lessened by Sumitomo Mitsui Trust Group Inc.July 5, 2025 | marketbeat.comPersonalis, Inc. (NASDAQ:PSNL) Given Consensus Rating of "Buy" by BrokeragesJuly 4, 2025 | marketbeat.comPersonalis (NASDAQ:PSNL) Trading Down 3.5% - Here's WhyJuly 3, 2025 | marketbeat.comPersonalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?July 3, 2025 | zacks.comPersonalis (NASDAQ:PSNL) Hits New 12-Month High - Here's WhyJuly 2, 2025 | marketbeat.comPersonalis (NASDAQ:PSNL) Trading 6.4% Higher - Should You Buy?June 30, 2025 | marketbeat.comThe 13% return this week takes Personalis' (NASDAQ:PSNL) shareholders one-year gains to 394%June 18, 2025 | finance.yahoo.comPersonalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock?June 17, 2025 | zacks.comPersonalis: Ultra-Sensitive Tech, Ultra-Sensitive RisksJune 8, 2025 | seekingalpha.comPersonalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCOJune 4, 2025 | finance.yahoo.comPersonalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCOJune 3, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCELC, HHLA, BDSX, and PSNL Company DescriptionsBiodesix NASDAQ:BDSX$0.36 +0.01 (+2.86%) Closing price 04:00 PM EasternExtended Trading$0.36 +0.01 (+1.39%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.Celcuity NASDAQ:CELC$13.94 +0.40 (+2.95%) Closing price 04:00 PM EasternExtended Trading$13.43 -0.51 (-3.69%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.HH&L Acquisition NYSE:HHLAHH&L Acquisition Co. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on healthcare or healthcare-related companies in Asian markets. HH&L Acquisition Co. was incorporated in 2020 and is based in Central, Hong Kong.Personalis NASDAQ:PSNL$6.43 +0.23 (+3.71%) Closing price 04:00 PM EasternExtended Trading$6.46 +0.03 (+0.53%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Block Levels Up: What S&P 500 Inclusion Means for Investors Steel Dynamics Stock Steady on Long-Term Prospects Amazon Stock Rally Hits New Highs: Buy Into Earnings? A Bullish Storm Is Brewing for High-Yield Verizon’s Share Price Forget the Hype—TSMC Is the AI Stock That Actually Delivers Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-Term Domino’s Delivers Another Discounted Entry for Income Investors Palantir Bulls and Bears Set for an August Showdown Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
